Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies

Ali H. D. Alshehri

Open source

DOI
10.3390/diagnostics14212407
Published
2024-10-29
Container
Diagnostics
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/diagnostics14212407,
  title = {Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies},
  author = {Ali H. D. Alshehri},
  year = {2024},
  journal = {Diagnostics},
  doi = {10.3390/diagnostics14212407},
  url = {https://doi.org/10.3390/diagnostics14212407}
}

RIS

TY  - JOUR
TI  - Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies
AU  - Ali H. D. Alshehri
PY  - 2024
JO  - Diagnostics
DO  - 10.3390/diagnostics14212407
UR  - https://doi.org/10.3390/diagnostics14212407
ER  - 

APA

Alshehri, A. H. D. (2024). Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies. Diagnostics. https://doi.org/10.3390/diagnostics14212407

Source records